Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma

Figure 1 Flow diagram of the participants analyzed. HCC: Hepatocellular carcinoma; PD-1: Programmed cell death-1.

Figure 2 Survival outcomes in the overall cohort. A: Overall survival; B: Progression-free survival.

Figure 3 Comparison of second-line treatment strategies. A: Overall survival; B: Progression-free survival in regorafenib combined with programmed cell death1 inhibitors group vs regorafenib monotherapy group. RP: Regorafenib combined with programmed cell death1 inhibitors; R: Regorafenib monotherapy.

Figure 4 Impact of prior first-line immune checkpoint inhibitor exposure on overall survival. A: Overall survival in patients without prior immune checkpoint inhibitor (ICI) combination; B: Overall survival in patients with prior ICI combination in the second-line regorafenib combined with programmed cell death1 inhibitors group vs regorafenib monotherapy group. RP: Regorafenib combined with programmed cell death1 inhibitors; R: Regorafenib monotherapy.

Figure 5 Influence of first-line tyrosine kinase inhibitor type on overall survival following second-line regorafenib-based therapy. A: Overall survival in regorafenib combined with programmed cell death1 inhibitors group; B: Overall survival in regorafenib monotherapy group, stratified by first-line lenvatinib vs sorafenib treatment.